Compounds > amifostine anhydrous

amifostine anhydrous and perfosfamide

amifostine anhydrous has been researched along with perfosfamide in 6 studies

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's6 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Chan, KW; Rodriguez, WC; Rogers, PC; Skala, JP1
Douay, L; Giarratana, MC; Gorin, NC; Hu, C1
Bearman, SI; Jones, RB; Myers, S; Purdy, M; Shpall, EJ; Stemmer, SM1
Bast, RC; Bearman, SI; Bonner, HS; Franklin, WA; Hami, L; McCulloch, W; Peters, WP; Shaw, L; Shpall, EJ; Stemmer, SM1
Bearman, SI; Cagnoni, PJ; Capizzi, R; Franklin, WA; Hami, L; Jones, RB; Ross, M; Schein, PS; Shpall, EJ1

Trials

3 trial(s) available for amifostine anhydrous and perfosfamide

ArticleYear
New strategies in marrow purging for breast cancer patients receiving high-dose chemotherapy with autologous bone marrow transplantation.
    Breast cancer research and treatment, 1993, Volume: 26 Suppl

    Topics: Amifostine; Antigens, CD; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Purging; Bone Marrow Transplantation; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Dose-Response Relationship, Drug; Doxorubicin; Female; Fluorouracil; Humans; Methotrexate; Stem Cells

1993
Amifostine (WR-2721) shortens the engraftment period of 4-hydroperoxycyclophosphamide-purged bone marrow in breast cancer patients receiving high-dose chemotherapy with autologous bone marrow support.
    Blood, 1994, Jun-01, Volume: 83, Issue:11

    Topics: Adult; Amifostine; Bone Marrow Purging; Bone Marrow Transplantation; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Female; Hematopoietic Stem Cells; Humans; Transplantation, Autologous

1994
Use of amifostine in bone marrow purging.
    Seminars in oncology, 1996, Volume: 23, Issue:4 Suppl 8

    Topics: Adult; Amifostine; Bone Marrow Purging; Bone Marrow Transplantation; Breast Neoplasms; Cyclophosphamide; Drug Therapy, Combination; Hematopoietic Stem Cells; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Middle Aged; Premedication; Treatment Outcome

1996

Other Studies

3 other study(ies) available for amifostine anhydrous and perfosfamide

ArticleYear
Effect of Ethiofos on cytotoxicity of pharmacological purging protocols used for autologous marrow grafts in acute lymphoblastic leukemia.
    Progress in clinical and biological research, 1992, Volume: 377

    Topics: Amifostine; Bone Marrow Purging; Bone Marrow Transplantation; Colony-Forming Units Assay; Cyclophosphamide; Hematopoietic Stem Cells; Humans; Neoplastic Stem Cells; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Transplantation, Autologous; Tumor Cells, Cultured; Tumor Stem Cell Assay

1992
Amifostine (WR-2721) protects normal haematopoietic stem cells against cyclophosphamide derivatives' toxicity without compromising their antileukaemic effects.
    European journal of cancer (Oxford, England : 1990), 1995, Volume: 31A Suppl 1

    Topics: Amifostine; Antineoplastic Agents; Bone Marrow Purging; Bone Marrow Transplantation; Cyclophosphamide; Dose-Response Relationship, Drug; Hematopoietic Stem Cells; Humans; Leukemia; Neoplastic Stem Cells

1995
Amifostine shortens bone marrow recovery period in breast cancer patients.
    Oncology (Williston Park, N.Y.), 1995, Volume: 9, Issue:1

    Topics: Amifostine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Marrow Transplantation; Breast Neoplasms; Cyclophosphamide; Humans; Leukocytes

1995